Investment Thesis
Trevi Therapeutics is a pre-revenue biopharmaceutical company burning $16.7M annually with only $19.4M in cash, implying approximately 1 year of financial runway. While the balance sheet is strong with minimal debt and $172.1M in equity, the company faces existential execution risk dependent on successful clinical development and capital raises.
Strengths
- Fortress balance sheet with $172.1M stockholders equity and near-zero liabilities ($7.5M)
- Exceptional liquidity position with 24.75x current ratio eliminating near-term bankruptcy risk
- Improving loss trajectory with net loss declining 31.9% year-over-year, suggesting operational optimization
Risks
- Zero revenue with no approved commercial products, representing fundamental business model risk
- Operating cash burn of $16.7M annually exhausts current cash reserves within approximately 12 months
- Pre-commercial execution risk: success entirely dependent on clinical trial outcomes, FDA approval, and future capital availability
- Negative returns (ROE -7.7%, ROA -7.3%) with no current path to profitability without product launches
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash balance - determines capital raise urgency
- Clinical pipeline advancement and FDA regulatory interactions for lead candidates
- Dilution impact and terms of future equity financing rounds
Financial Metrics
Revenue
N/A
Net Income
-13.2M
EPS (Diluted)
$-0.09
Free Cash Flow
-16.8M
Total Assets
179.6M
Cash
19.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-7.7%
ROA
-7.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
24.75x
Quick Ratio
24.75x
Debt/Equity
0.00x
Debt/Assets
4.2%
Interest Coverage
-7,456.00x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:50:17.463132 |
Data as of: 2026-03-31 |
Powered by Claude AI